

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 20 NO 2 JUNE 2003

ISSN 0790-9667



'Jet Plane, Blue, Red, Yellow, Green, Boxes, Arrows on Grand Parade, Chinese Version'

(detail) by John the Painter (gouache on brown paper, 214 x 511 cm)

From an exhibition at the Irish Museum of Modern Art, Royal Hospital Kilmainham, Dublin 8.

*In a broad
spectrum of
patients...*

*...See the difference
GEODON can make*

Abbreviated Prescribing Information for Geodon (ziprasidone). Republic of Ireland Geodon™. Presentation: Capsules containing ziprasidone hydrochloride monohydrate equivalent to 20, 40, 60 and 80mg ziprasidone. Indications: Treatment of schizophrenia Dosage: Acute treatment - 40mg twice daily with food. Maximum dosage of 80mg twice daily may be reached by day 3 of treatment. Maintenance treatment - use the lowest effective dose. In elderly: A lower starting dose should be considered for patients over 65 where clinical factors warrant. In children: Caution as no evaluation under 18 years of age. In renal impairment: No dosage adjustment required. In hepatic impairment: Consider lower doses in hepatic insufficiency. Caution in severe hepatic insufficiency. Contra-indications: Known hypersensitivity to any ingredient of the product. Known QT-interval prolongation. Congenital long QT syndrome. Recent acute myocardial infarction. Uncompensated heart failure. Arrhythmias treated with class IA and III antiarrhythmic drugs. Concomitant treatment with medicines known to prolong the QT interval. Special warnings: A medical history, family history and physical examination should be undertaken to identify patients for whom ziprasidone is not recommended. Mild to moderate dose-related QT-interval prolongation, therefore, do not give together with medicinal products known to prolong the QT interval. Caution in patients with significant bradycardia. Before treatment is started - correct electrolyte disturbances; and as with other drugs which prolong QT interval, consider ECG review in patients with stable cardiac disease. If cardiac symptoms occur, consider the possibility of a malignant cardiac arrhythmia and perform a cardiac evaluation, including an ECG. It is recommended to stop treatment if the QT interval is >500msec. No cases of Neuroleptic Malignant Syndrome (NMS) seen in clinical trials, but potential risk cannot be excluded. Management of NMS should included immediate withdrawal of all antipsychotic drugs. Potential to cause tardive dyskinesia, if signs appear consider dose reduction or discontinuation. Caution in patients with a history of seizures. Interactions: ziprasidone should not be given with medicinal products known to prolong the QT interval (see SPC for details). Caution in combination with other centrally acting drugs and alcohol. Ziprasidone is unlikely to cause clinically important drug interactions mediated by CYP3A4 or CYP2D6 (see SPC for details). Pregnancy and lactation: Not recommended unless the expected benefit outweighs the risk. Women of childbearing potential should use an appropriate method of contraception. Avoid breast-feeding. Driving: Ziprasidone may cause somnolence, therefore caution patients likely to drive or operate machines. Undesirable effects: In short term placebo controlled trials: >1/10 somnolence; >1/100, <1/100 asthenia, headache, constipation, dry mouth, dyspepsia, increased salivation, nausea, vomiting, agitation, akathisia, dizziness, dystonia, extrapyramidal syndrome, hypertonia, tremor, abnormal vision; >1/1000, <1/100 pain, postural hypotension, tachycardia, flatulence, thirst, joint disorder, leg cramps, cogwheel rigidity, paresthesia, speech disorder, tardive dyskinesia, rhinitis, rash, urticaria. In long term maintenance trials: elevated prolactin levels, returning to normal without cessation of treatment and rare reports of clinical manifestation (gynaecomastia and breast enlargement). Legal Category: POM. Package quantities: blister packs containing 56 capsules. Further information on request: Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. Marketing Authorisation numbers: PA 19/52/5. Date of first authorisation/renewal of the authorisation: February 2002. Date of revision of the text: February 2002. Date of revision of the text: February 2002. <http://www.pfizer.com> 1607/04/2002 066700007552

MAKE THE SWITCH

GEODON™

(ziprasidone HCl)

See the difference



Published online by Cambridge University Press

Editor-in-Chief: Brian A Lawlor

Production Editor:
Anne Henrichsen

Advertising Manager:
Helen Martin

Administrator:
Andrea McAdam

Founding Editor: Mark Hartman

Associate Editors:
Ted Dinan (Cork), David King (Belfast)

Editorial Board: Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Brian O'Shea (Wicklow), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Victoria)

Statistical Editor:
Ronan Conroy (Dublin)

Submissions & correspondence to:
The Editor,
Irish Journal of Psychological Medicine,
25 Adelaide Street,
Dun Laoghaire,
Co Dublin, Ireland.

Telephone: 00-353-1-2803967

Fax: 00-353-1-2807076

Email: psychological@medmedia.ie

Website: www.ijpm.org

Publisher

MedMedia Ltd.
25 Adelaide Street, Dun Laoghaire,
Co Dublin, Ireland.

Printing: W&G Bairds Ltd

Subscriptions

Rates per volume of four issues
(Mar, Jun, Sept, Dec) Price Regions:
EU countries: €107, Stg65
Rest of World: €126, \$111
Incl. airmail postage internationally.

Subscription enquiries, orders and cheques made payable to:

Turpin Distribution Service Ltd
Blackhorse Road, Letchworth
SG6 1HN, England.
Tel : +44 01462 672555
Fax: + 44 01462 480947
Email: CustServTurpin@turpinltd.com
www.turpin-distribution.com

Circulation

2,200 to 54 countries.
The Journal participates in the World Health Organisation project to improve distribution of scientific materials on mental health. Publication does not imply endorsement. Limited photocopying authorisation granted for a fee to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA, or to appropriate Reproduction Rights Organisation; isolated non-profit, academic photocopying excepted.

Editorial

38 Psychotherapy and learning disability

Philip Dodd, Maria McGinnity

Original papers

41 Costing the hospital-based process of resettling people with learning disability in the community

Damien M Hughes, Maria McGinnity, John Kell, Oscar Kennedy, Michael Donnelly

45 Meeting the needs of people with schizophrenia living in the community: a report from a European collaboration

Fiona Keogh, Aine Finnerty, Anne O'Grady Walshe, Ian Daly, Denis Murphy, Abbie Lane, Dermot Walsh

Brief reports

52 The use of HoNESCA in a child and adolescent mental health service

Julie Manderson, Noel McCune

56 Secular trends in the mental health of primary school children

Paul McArdle, Jonathan Prosser, Heather Dickinson, Israel Kolvin

Audits

59 An audit of psychotropic prescribing practice of general adult psychiatrists in elderly demented patients

Anna Maria Meaney, Colm Cooney

Perspectives

65 Liaison psychiatry in rural general practice

Vincent Russell, MacDara McCauley, John MacMahon, Sheila Casey, Heather McCullagh, Jillian Begley

Case reports

69 Treatment of early onset bipolar disorder, NOS with low dose Carbamazepine

Fiona McNicholas, Laura McKenna

40 Subscriptions

52a John Dunne Medal

58 Guidelines for Authors

72 Letters to the Editor

72 Book Reviews

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

I too had a life, filled with laughter and tears.

we made Wonderful

PLANS

for our later years.

And now here I am, in this world of my own.

I'M Lost and I'M frightened, and feel all alone.

Because of my illness, I'm no longer the same,


BUT reach out AND touch me

I'm more than a name.

MORE THAN A NAME by Jerry Ham (Alzheimer's carer)

 **once daily**
Aricept
donepezil hydrochloride

Making a difference in Alzheimer's



Abbreviated Prescribing Information for ARICEPT™ (donepezil)
Republic of Ireland
ARICEPT™ (donepezil hydrochloride) Please refer to the SmPC before prescribing ARICEPT 5 mg or ARICEPT 10 mg. **Indication:** Symptomatic treatment of mild to moderately severe Alzheimer's dementia. **Dose and administration:** Adults/elderly: 5 mg daily which may be increased to 10 mg once daily after at least one month. No dose adjustment necessary for patients with renal impairment. Dose escalation, according to tolerability, should be performed in patients with mild to moderate hepatic impairment. **Children:** Not recommended. **Contra-Indications:** Pregnancy. Hypersensitivity to donepezil, piperidine derivatives or any excipients used in ARICEPT. **Lactation:** Excretion into breast milk unknown. Women on donepezil should not breast feed. **Warnings and**

Precautions: Initiation and supervision by a physician with experience of Alzheimer's dementia. A caregiver should be available to monitor compliance. Regular monitoring to ensure continued therapeutic benefit, consider discontinuation when evidence of a therapeutic effect ceases. Exaggeration of succinylcholine-type muscle relaxation. Avoid concurrent use of anticholinesterases, cholinergic agonists, cholinergic antagonists. Possibility of vagotonic effect on the heart which may be particularly important with "sick sinus syndrome", and supraventricular conduction conditions. There have been reports of syncope and seizures - in such patients the possibility of heart block or long sinusal pauses should be considered. Careful monitoring of patients at risk of ulcer disease including those receiving NSAIDs. Cholinomimetics may cause bladder outflow obstruction. Seizures occur in Alzheimer's disease and cholinomimetics have the potential to cause seizures and they may also have the potential to exacerbate or

induce extrapyramidal symptoms. Care in patients suffering asthma and obstructive pulmonary disease. As with all Alzheimer's patients, routine evaluation of ability to drive/operate machinery. No data available for patients with severe hepatic impairment. **Drug Interactions:** Experience of use with concomitant medications is limited, consider possibility of as yet unknown interactions. Interaction possible with inhibitors or inducers of Cytochrome P450; use such combinations with care. Possible synergistic activity with succinylcholine-type muscle relaxants, beta-blockers, cholinergic or anticholinergic agents. **Side effects:** Most commonly diarrhoea, muscle cramps, fatigue, nausea, vomiting, and insomnia. Common effects (>1/100, <1/10): common cold, anorexia, hallucinations, agitation, aggressive behaviour, syncope, dizziness, insomnia, diarrhoea, vomiting, nausea, abdominal disturbance, rash, pruritis, muscle cramps, urinary incontinence, headache, fatigue, pain, accident. Uncommon effects (>1/1000, <1/100):

seizure, bradycardia, gastrointestinal haemorrhage, gastric & duodenal ulcers, minor increases in serum creatine kinase. Rare (>1/100,000, <1/10,000): extrapyramidal symptoms, sino-atrial block, atrioventricular block, liver dysfunction including hepatitis. **Legal Category:** POM. **Presentation:** Blister packed in strips of 14. ARICEPT 5 mg; white, film coated tablets marked 5 and Aricept, packs of 28. ARICEPT 10 mg; yellow, film coated tablets marked 10 and Aricept, packs of 28. **Marketing authorisation numbers:** ARICEPT 5 mg; PA 822/2/1. ARICEPT 10 mg; PA 822/2/2. **Marketing authorisation holder:** Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. **Further information from/Marketed by:** Pfizer (Ireland) Limited, Parkway House, Ballymount Road Lower, Dublin 12, Republic of Ireland. **Date of preparation:** January 2002



1002-04-01